Yahoo
KSE - Delayed Quote KRW

Dong-A Pharmaceutical Co.,Ltd. (000640.KS)

87,300.00 +400.00 (+0.46%)
At close: 3:30:30 PM GMT+9
View in AlphaSpace Currency in KRW All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
1,517,858,863.85
1,429,766,810.73
1,333,229,636.66
1,132,002,860.40
1,014,860,897.95
Cost of Revenue
1,032,099,283.06
973,117,954.24
925,164,455.01
757,128,910.78
720,475,309.23
Gross Profit
485,759,580.79
456,648,856.49
408,065,181.65
374,873,949.62
294,385,588.72
Operating Expense
378,400,294
358,875,882
325,970,515
297,992,227
256,530,762
Operating Income
107,359,286.79
97,772,974.49
82,094,666.65
76,881,722.62
37,854,826.72
Net Non Operating Interest Income Expense
-18,127,925.55
-25,643,399.80
-25,388,091.13
-18,351,210.03
-12,364,496.13
Pretax Income
84,525,935.14
54,061,466.89
76,337,803.20
65,733,730.90
17,608,580.03
Tax Provision
-348,056.39
-37,405,022.97
18,764,403.84
9,870,691.18
9,773,384.39
Net Income Common Stockholders
85,250,102.72
90,944,551.52
58,022,061.47
57,989,523.14
11,152,789.45
Basic EPS
13.02k
13.72k
8.49k
8.74k
1.68k
Diluted EPS
13.02k
13.72k
8.49k
8.74k
1.68k
Basic Average Shares
6,569.05
6,629.36
6,830.40
6,631.57
6,632.28
Diluted Average Shares
6,569.05
6,629.36
6,830.40
6,631.57
6,632.28
Total Operating Income as Reported
107,359,286.62
97,772,974.66
82,094,664.92
76,881,723.04
37,854,827.13
Rent Expense Supplemental
1,451,181
766,282
366,924
288,031
896,501
Total Expenses
1,410,499,577.06
1,331,993,836.24
1,251,134,970.01
1,055,121,137.78
977,006,071.23
Net Income from Continuing & Discontinued Operation
85,250,102.72
90,944,551.52
58,022,061.47
57,989,523.14
11,152,789.45
Normalized Income
108,157,204.52
119,960,213.80
69,277,892.19
60,612,921.17
15,823,772.33
Interest Income
--
3,024,037
3,979,270
4,380,564
2,454,123
Interest Expense
--
28,652,216
29,293,843
22,745,717
14,853,870
Net Interest Income
-18,127,925.55
-25,643,399.80
-25,388,091.13
-18,351,210.03
-12,364,496.13
EBIT
92,299,995.19
82,713,682.89
105,631,646.20
88,479,447.90
32,462,450.03
EBITDA
108,125,411.19
178,089,380.89
194,865,552.20
162,650,356.90
103,195,827.03
Reconciled Cost of Revenue
1,032,099,283.06
973,117,954.24
925,164,455.01
757,128,910.78
720,475,309.23
Reconciled Depreciation
15,825,416
95,375,698
89,233,906
74,170,909
70,733,377
Net Income from Continuing Operation Net Minority Interest
85,250,102.72
90,944,551.52
58,022,061.47
57,989,523.14
11,152,789.45
Total Unusual Items Excluding Goodwill
-38,178,503
-38,178,503
-14,924,347
-3,086,938
-6,442,735
Total Unusual Items
-38,178,503
-38,178,503
-14,924,347
-3,086,938
-6,442,735
Normalized EBITDA
146,303,914.19
216,267,883.89
209,789,899.20
165,737,294.90
109,638,562.03
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-15,271,401.20
-9,162,840.72
-3,668,516.28
-463,539.97
-1,771,752.13
12/31/2022 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: